124 related articles for article (PubMed ID: 15811143)
1. Clinical implications of N epsilon-(carboxymethyl)lysine, advanced glycation end product, in children and adolescents with type 1 diabetes.
Hwang JS; Shin CH; Yang SW
Diabetes Obes Metab; 2005 May; 7(3):263-7. PubMed ID: 15811143
[TBL] [Abstract][Full Text] [Related]
2. The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes.
Berg TJ; Clausen JT; Torjesen PA; Dahl-Jørgensen K; Bangstad HJ; Hanssen KF
Diabetes Care; 1998 Nov; 21(11):1997-2002. PubMed ID: 9802757
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.
Miura J; Yamagishi Si; Uchigata Y; Takeuchi M; Yamamoto H; Makita Z; Iwamoto Y
J Diabetes Complications; 2003; 17(1):16-21. PubMed ID: 12505751
[TBL] [Abstract][Full Text] [Related]
4. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA.
Galler A; Müller G; Schinzel R; Kratzsch J; Kiess W; Münch G
Diabetes Care; 2003 Sep; 26(9):2609-15. PubMed ID: 12941727
[TBL] [Abstract][Full Text] [Related]
5. Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy.
Ghanem AA; Elewa A; Arafa LF
Eur J Ophthalmol; 2011; 21(1):48-54. PubMed ID: 20544678
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema.
Boehm BO; Schilling S; Rosinger S; Lang GE; Lang GK; Kientsch-Engel R; Stahl P
Diabetologia; 2004 Aug; 47(8):1376-9. PubMed ID: 15258735
[TBL] [Abstract][Full Text] [Related]
7. Increased levels of N(ε)- Carboxy methyl lysine (N(ε)-CML) are associated with topographic alterations in retinal pigment epithelium: A preliminary study.
Mishra N; Saxena S; Ruia S; Prasad S; Singh V; Khanna V; Staffa R; Gaspar L; Kruzliak P
J Diabetes Complications; 2016 Jul; 30(5):868-72. PubMed ID: 27039312
[TBL] [Abstract][Full Text] [Related]
8. Increased levels of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine in type 1 diabetic patients with impaired renal function: correlation with markers of endothelial dysfunction.
Lieuw-A-Fa ML; van Hinsbergh VW; Teerlink T; Barto R; Twisk J; Stehouwer CD; Schalkwijk CG
Nephrol Dial Transplant; 2004 Mar; 19(3):631-6. PubMed ID: 14767019
[TBL] [Abstract][Full Text] [Related]
9. Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.
Engelen L; Persson F; Ferreira I; Rossing P; Hovind P; Teerlink T; Stehouwer CD; Parving HH; Schalkwijk CG
Nephrol Dial Transplant; 2011 Nov; 26(11):3573-7. PubMed ID: 21385863
[TBL] [Abstract][Full Text] [Related]
10. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients.
Wautier MP; Massin P; Guillausseau PJ; Huijberts M; Levy B; Boulanger E; Laloi-Michelin M; Wautier JL
Diabetes Metab; 2003 Feb; 29(1):44-52. PubMed ID: 12629447
[TBL] [Abstract][Full Text] [Related]
11. Role of N-ε- carboxy methyl lysine, advanced glycation end products and reactive oxygen species for the development of nonproliferative and proliferative retinopathy in type 2 diabetes mellitus.
Choudhuri S; Dutta D; Sen A; Chowdhury IH; Mitra B; Mondal LK; Saha A; Bhadhuri G; Bhattacharya B
Mol Vis; 2013; 19():100-13. PubMed ID: 23378723
[TBL] [Abstract][Full Text] [Related]
12. Association of serum N(ε)-Carboxy methyl lysine with severity of diabetic retinopathy.
Mishra N; Saxena S; Shukla RK; Singh V; Meyer CH; Kruzliak P; Khanna VK
J Diabetes Complications; 2016 Apr; 30(3):511-7. PubMed ID: 26782022
[TBL] [Abstract][Full Text] [Related]
13. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations.
Hammes HP; Brownlee M; Lin J; Schleicher E; Bretzel RG
Diabetologia; 1999 May; 42(5):603-7. PubMed ID: 10333054
[TBL] [Abstract][Full Text] [Related]
14. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
[TBL] [Abstract][Full Text] [Related]
15. Autoantibody against N(epsilon)-(carboxymethyl)lysine: an advanced glycation end product of the Maillard reaction.
Shibayama R; Araki N; Nagai R; Horiuchi S
Diabetes; 1999 Sep; 48(9):1842-9. PubMed ID: 10480617
[TBL] [Abstract][Full Text] [Related]
16. Small- and large-fiber neuropathy after 40 years of type 1 diabetes: associations with glycemic control and advanced protein glycation: the Oslo Study.
Sveen KA; Karimé B; Jørum E; Mellgren SI; Fagerland MW; Monnier VM; Dahl-Jørgensen K; Hanssen KF
Diabetes Care; 2013 Nov; 36(11):3712-7. PubMed ID: 24026557
[TBL] [Abstract][Full Text] [Related]
17. Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes.
Hirata K; Kubo K
Endocr J; 2004 Dec; 51(6):537-44. PubMed ID: 15644571
[TBL] [Abstract][Full Text] [Related]
18. Antibodies against advanced glycation end product Nepsilon-(carboxymethyl)lysine in healthy controls and diabetic patients.
Vay D; Vidali M; Allochis G; Cusaro C; Rolla R; Mottaran E; Bellomo G; Albano E
Diabetologia; 2000 Nov; 43(11):1385-8. PubMed ID: 11126407
[TBL] [Abstract][Full Text] [Related]
19. N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 diabetes: role of renal function.
Wagner Z; Wittmann I; Mazák I; Schinzel R; Heidland A; Kientsch-Engel R; Nagy J
Am J Kidney Dis; 2001 Oct; 38(4):785-91. PubMed ID: 11576882
[TBL] [Abstract][Full Text] [Related]
20. Improvement in quality of diabetes control and concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus studied over a period of 10 years (JEVIN).
Schiel R; Franke S; Appel T; Voigt U; Ross IS; Kientsch-Engel R; Stein G; Müller UA
J Diabetes Complications; 2003; 17(2):90-7. PubMed ID: 12614975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
